Q2 FY2026 EarningsQ2 FY26 beat consensus on both top and bottom lines: revenue of $0.91M vs. $0.70M expected, and GAAP EPS of -$0.06 vs. -$0.07 expected. Gross margin significantly outperformed at 84.3% vs. 82.5% consensus. The revenue beat was driven by rapid expansion of the RenovoCath commercial footprint, ending the quarter with 21 active centers, while management raised expectations for 2H FY26 revenue to exceed original full-year forecasts.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: RenovoRx(RNXT) the Revenue is 909 K (+115.4%), Beat estimate;the EBIT is -3.349 M (-25.06%), Beat estimate;the EPS is -0.06 (+25%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B115.40%
0.00B66.77%
+0.00B48.63%
EBITExceed expectations
-0.00B25.06%
-0.00B26.34%
+0.00B1.28%
EPSExceed expectations
-0.0625.00%
-0.07259.38%
+0.012515.62%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf